HIV clade B DNA vaccine (PENNVAX-B) - Inovio

Drug Profile

HIV clade B DNA vaccine (PENNVAX-B) - Inovio

Alternative Names: DNA vaccine for prevention of HIV clade B infection - Inovio; PENNVAX-B

Latest Information Update: 09 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals; University of Pennsylvania
  • Class AIDS vaccines; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 12 May 2014 Pharmacodynamics data from a phase I trial in HIV infections (in volunteers) released by Inovio Pharmaceuticals
  • 10 Jul 2013 Immunogenicity data from the HVTN 070 and HVTN 080 phase I trials in HIV-1 infections released by Inovio Pharmaceuticals
  • 08 Nov 2012 Inovio Pharmaceuticals completes a phase I trial in HIV-1 infections in USA (NCT01082692)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top